申请人:Lu Canzhong
公开号:US09193718B2
公开(公告)日:2015-11-24
This invention provides a class of quinazoline compounds, as represented by formula (I), and their pharmaceutically acceptable salts,
wherein: each of R1 and R2 independently, is selected from H, C1-C6 alkoxy, halo-C1-C6 alkoxy, C1-C6-alkoxy-C1-C6 alkoxy, C3-C8 cycloalkoxy, C3-C8 heterocycloalkoxy containing at least one of heteroatoms selected from N, O, S; Z is —NR4—, C(R5)2, S or —O—, wherein R4 is H or C1-C3 alkyl, R5 is the same or different, selected from H or C1-C3 alkyl; R3 is selected from H, halogen, C1-C6 alkyl, C1-C6 alkoxy or halo-C1-C6 alkyl; n is an integer from 0 to 5. This invention also provides methods of preparation and medical uses of the compounds of formula (I) and their pharmaceutically acceptable salts. These compounds have the activity of inhibiting EGFR-TK, and can be used as drugs for the treatment of protein tyrosine kinase related diseases such as tumors, cancers, etc.
本发明提供了一类喹唑啉化合物,如式(I)所示,以及它们的药学上可接受的盐,其中:R1和R2中的每一个独立地选择自H、C1-C6烷氧基、卤代C1-C6烷氧基、C1-C6-烷氧基-C1-C6烷氧基、C3-C8环烷氧基、含有至少一个从N、O、S中选择的杂原子的C3-C8杂环烷氧基;Z是—NR4—、C(R5)2、S或—O—,其中R4是H或C1-C3烷基,R5相同或不同,选择自H或C1-C3烷基;R3选择自H、卤素、C1-C6烷基、C1-C6烷氧基或卤代C1-C6烷基;n是0到5的整数。本发明还提供了制备方法和化合物的医药用途。这些化合物具有抑制EGFR-TK的活性,可用作治疗蛋白酪氨酸激酶相关疾病如肿瘤、癌症等的药物。